v3.25.1
Segment Information - Schedule of Reportable Segments Reconcile of Segment Information (Details) - Operating Segments - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Cost of drugs $ 7,368,426 $ 5,291,630 $ 4,142,064
Cost of services 797,286 711,304 917,140
Other direct costs 640,075 549,086 493,340
Segment selling, general, and administrative expenses 802,253 737,268 703,683
Segment depreciation and amortization expense 135,778 138,646 138,154
Segment EBITDA 599,952 540,374 518,135
Products      
Segment Reporting Information [Line Items]      
Revenues 8,754,282 6,522,450 5,264,423
Services      
Segment Reporting Information [Line Items]      
Revenues 1,317,932 1,168,566 1,373,033
Pharmacy Solutions      
Segment Reporting Information [Line Items]      
Cost of drugs 7,368,426 5,291,630 4,142,064
Other direct costs 640,075 549,086 493,340
Segment selling, general, and administrative expenses 462,219 426,521 398,080
Segment depreciation and amortization expense 111,103 115,749 113,532
Segment EBITDA 394,665 370,962 344,472
Pharmacy Solutions | Products      
Segment Reporting Information [Line Items]      
Revenues 8,754,282 6,522,450 5,264,423
Provider Services      
Segment Reporting Information [Line Items]      
Cost of services 797,286 711,304 678,181
Segment selling, general, and administrative expenses 340,034 310,747 288,762
Segment depreciation and amortization expense 24,675 22,897 22,478
Segment EBITDA 205,287 169,412 153,918
Provider Services | Services      
Segment Reporting Information [Line Items]      
Revenues $ 1,317,932 $ 1,168,566 1,098,383
Other      
Segment Reporting Information [Line Items]      
Cost of services     238,959
Segment selling, general, and administrative expenses     16,841
Segment depreciation and amortization expense     2,144
Segment EBITDA     19,745
Other | Services      
Segment Reporting Information [Line Items]      
Revenues     $ 274,650